Summary & Overview
CPT 87900: Viral Drug Susceptibility Testing, Genotype-to-Phenotype Prediction
CPT code 87900 denotes a laboratory test that predicts a virus’s susceptibility or resistance to antiviral medications by comparing patient-derived data with updated genotypic bioinformatics to infer phenotype. This molecular/virology diagnostic supports clinicians in selecting appropriate antiviral therapy and can influence treatment effectiveness, antimicrobial stewardship, and downstream healthcare utilization nationally.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for genotypic-to-phenotypic antiviral testing, typical settings where this service is performed (clinical and hospital laboratories), and what payers commonly consider when determining coverage. The publication summarizes benchmarks and payer policy themes relevant to molecular virology testing, highlights common billing considerations, and notes areas where coding clarity or policy updates may affect claims processing.
This executive summary is intended for a national audience of clinicians, laboratory managers, and revenue cycle professionals seeking concise information on the clinical purpose of CPT code 87900, the primary payers involved, and the types of operational and policy topics that affect use and reimbursement.
Billing Code Overview
CPT code 87900 describes a laboratory procedure in which an analyst evaluates a patient specimen to predict susceptibility or resistance of a virus to antiviral drugs. The test uses patient-derived data compared to regularly updated genotypic bioinformatics to infer a phenotypic response to specific antiviral agents.
Service Type: Viral drug susceptibility testing using genotypic-to-phenotypic bioinformatics interpretation
Typical Site of Service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with chronic hepatitis C infection presents to the infectious disease clinic after prior antiviral therapy failure. The clinician orders a viral phenotypic susceptibility analysis to guide next-line antiviral selection. A blood specimen is collected in the outpatient phlebotomy lab and sent to a molecular diagnostics laboratory. The lab analyst performs a genotype-based bioinformatics comparison to a regularly updated resistance database and reports predicted phenotype susceptibility or resistance to specific antiviral agents. Results are routed to the ordering clinician through the electronic health record; the clinician reviews the report during a follow-up visit or telehealth encounter to decide on an optimized antiviral regimen.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation of the test report separate from the technical work. |
TC | Technical component | Use when reporting only the technical component (laboratory processing, sequencing, analysis) without professional interpretation. |